BE1001845A4 - Proteines qui inhibent l'activite due au facteur de necrose tumorale. - Google Patents

Proteines qui inhibent l'activite due au facteur de necrose tumorale. Download PDF

Info

Publication number
BE1001845A4
BE1001845A4 BE8900350A BE8900350A BE1001845A4 BE 1001845 A4 BE1001845 A4 BE 1001845A4 BE 8900350 A BE8900350 A BE 8900350A BE 8900350 A BE8900350 A BE 8900350A BE 1001845 A4 BE1001845 A4 BE 1001845A4
Authority
BE
Belgium
Prior art keywords
sep
fnta
protein
inhibitor
inh
Prior art date
Application number
BE8900350A
Other languages
English (en)
French (fr)
Inventor
Jean-Michel Dayer
Philippe Lucien Seckinger
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1001845A4 publication Critical patent/BE1001845A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BE8900350A 1988-03-31 1989-03-30 Proteines qui inhibent l'activite due au facteur de necrose tumorale. BE1001845A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888807803A GB8807803D0 (en) 1988-03-31 1988-03-31 Biochemical product

Publications (1)

Publication Number Publication Date
BE1001845A4 true BE1001845A4 (fr) 1990-03-20

Family

ID=10634493

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900350A BE1001845A4 (fr) 1988-03-31 1989-03-30 Proteines qui inhibent l'activite due au facteur de necrose tumorale.

Country Status (12)

Country Link
JP (1) JPH02117700A (sv)
KR (1) KR890014125A (sv)
AU (1) AU3228789A (sv)
BE (1) BE1001845A4 (sv)
DE (1) DE3910323A1 (sv)
DK (1) DK156589A (sv)
FR (1) FR2629345A1 (sv)
GB (2) GB8807803D0 (sv)
IL (1) IL89804A0 (sv)
IT (1) IT1232827B (sv)
NL (1) NL8900779A (sv)
SE (1) SE8901115L (sv)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
AU630497B2 (en) * 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
EP0480389A1 (de) * 1990-10-12 1992-04-15 Hoechst Aktiengesellschaft Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung
DK0567566T4 (da) * 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
JPH06510122A (ja) * 1991-08-23 1994-11-10 エヌチップ　インコーポレイテッド パッケージされていない集積回路のバーン・イン技術
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN106456751B (zh) 2014-03-31 2021-02-02 安姆根K-A有限公司 治疗指甲和头皮银屑病的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 41, 1988, pages 414-419; C. PEETRE et al.: "A tumor necrosis factor binding protein is present in human biological fluids" *
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 167, avril 1988, pages 1511-1516, The Rockefeller University Press; P. SECKINGER et al.: "A human inhibitor of tumor necrosis factor alpha" *

Also Published As

Publication number Publication date
JPH02117700A (ja) 1990-05-02
AU3228789A (en) 1989-10-05
KR890014125A (ko) 1989-10-21
SE8901115D0 (sv) 1989-03-30
SE8901115L (sv) 1989-10-01
GB2218101A (en) 1989-11-08
FR2629345A1 (fr) 1989-10-06
GB8807803D0 (en) 1988-05-05
GB8907148D0 (en) 1989-05-10
IT8947794A0 (it) 1989-03-30
NL8900779A (nl) 1989-10-16
IT1232827B (it) 1992-03-05
DK156589A (da) 1989-10-01
DE3910323A1 (de) 1989-10-19
IL89804A0 (en) 1989-09-28
DK156589D0 (da) 1989-03-30

Similar Documents

Publication Publication Date Title
BE1001845A4 (fr) Proteines qui inhibent l'activite due au facteur de necrose tumorale.
KR920007399B1 (ko) 인체 생리적 활성 폴리펩티드
JP3367581B2 (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
CA2094705C (fr) Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne
JPH03503641A (ja) 発現のための突然変異体ヒトアンギオゲニン（卓越したアンギオゲニン活性を有する血管形成誘導因子）遺伝子及び発現方法
JP2002502235A (ja) 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
JP2002531050A (ja) 抗メチオニンおよび抗ホモシステイン化学療法におけるメチオニナーゼの使用
JP2757987B2 (ja) ヒト抗‐炎症ホスホリパーゼ阻害蛋白
JP2764264B2 (ja) 線溶活性増強剤
JPH0229317B2 (sv)
FR2623400A1 (fr) Facteur d'activation des neutrophiles
JPS61111693A (ja) λＰ▲Ｌの下つき▼プロモ−タ−とリボソ−ム結合部位の置換に便利なように工学処理した制限部位とを含有する発現ベクタ−、このベクタ−を含有するプラスミド、このプラスミドを含有する宿主、および関連方法
JPH10504441A (ja) Ｔｎｆ形成阻害のための組成物およびその使用
JPH03155787A (ja) Ｅｂｚｄ蛋白質発現系
JP2863265B2 (ja) インターロイキン１インヒビター
JPH06107693A (ja) 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
CA2001107A1 (fr) Procede d'isolement d'interleukine-2 glycosylee
JPS63503354A (ja) ミンアクチビンをコードするｄｎａ分子
JP2002541120A (ja) 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤
EP0686194A1 (fr) Facteurs de croissance de la famille de l'harp, procede d'obtention et applications
US6586225B2 (en) ICE/CED-3 like protease designated FMH-1
FR2562088A1 (fr) Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
JP3904584B2 (ja) ヒト由来プロスタサイクリンシンターゼ
Beutler et al. Cachectin (tumor necrosis factor) and lymphotoxin as primary mediators of tissue catabolism, inflammation, and shock

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: GLAXO GROUP LTD

Effective date: 19910331